jueves, 19 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleNasdaq· June 26, 2026

Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired

View original at nasdaq.com
Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired (RTTNews) - This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease, neurology and immunology…
Opening lines of the source · Nasdaq · short snapshot: read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The workforce reduction is projected to deliver $10 million in annualised cost savings.

    60% confidence
  • ADC Therapeutics maintains a cash runway into 2028, supporting ongoing regulatory and clinical plans for ZYNLONTA combinations.

    60% confidence
  • DT120 ODT was generally well tolerated, with no serious adverse events or suicidality signal.

    60% confidence
  • Merck KGaA expects to realise annual cost savings of approximately 140 million euros by the third year following the Bio-Techne deal closure.

    60% confidence
  • The company plans to resubmit the Cytisinicline NDA in Q4 2026, targeting a potential approval in H1 2027 if no further major issues arise.

    60% confidence

Citado en estos reportajes de Via News

Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired: Source | Via News | es.via.news